Sunshine Biopharma Inc. (SBFM) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Sunshine Biopharma Inc. is a pharmaceutical company operating primarily through two Canadian subsidiaries: Nora Pharma Inc., which markets 74 generic prescription drugs in Canada, and Sunshine Biopharma Canada Inc., which develops and sells OTC supplements. The company is also developing proprietary drugs, including K1.1 mRNA for liver cancer and SBFM-PL4 for SARS Coronavirus infections. The company is classified as a Smaller Reporting Company.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Revenue | $9,410,230 | $18,311,571 | $16,844,113 |
| Gross Profit | $3,422,866 | $6,153,292 | $4,710,594 |
| Gross Margin | 36.4% | 33.6% | 28.0% |
| Net Loss | $(1,770,834) | $(2,950,605) | $(1,778,101) |
| EPS (Basic) | $(0.39) | $(0.82) | $(43.48) |
| Cash & Equivalents | $10,305,320 (as of June 30, 2025) | ||
| Total Assets | $31,965,250 | ||
| Total Liabilities | $6,280,446 | ||
| Operating Cash Flow (YTD) | $(2,987,267) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 8.7% year-over-year for the six months ended June 30, 2025, driven by enhanced marketing efforts.
- Margin Expansion: Gross margin improved significantly from 28.0% in YTD 2024 to 33.6% in YTD 2025 due to better procurement costs for finished products.
- Intangible Asset Impairment: A non-cash impairment charge of $1,061,809 was recorded in Q2 2025 due to the determination that certain product licenses could not be commercialized. This significantly impacted operating income.
- Expense Increases: General & Administrative expenses rose due to the impairment charge, increased consulting fees related to warrant exercises, and higher salaries from new hiring.
- Capital Structure: The company completed a registered direct offering in April 2025, raising net proceeds of approximately $1.83 million. Additionally, significant warrant exercises occurred, increasing common shares outstanding from 2.58 million (Dec 2024) to 4.56 million (June 2025).
Outlook, Risks, and Management Commentary
- Liquidity: Management believes existing cash ($10.3M) and operating cash flow will fund operations for the next 24 months. However, no committed capital sources exist, and future fundraising may be necessary for R&D and expansion.
- Strategic Goals: The company aims to reduce the cost of goods sold from ~65% to ~60% to reach breakeven. They plan to launch 17 additional generic drugs in 2026.
- Legal Contingency: Following the termination of Nora Pharma's former president (Mr. Malek Chamoun) for cause in April 2025, the company received a demand letter requesting approximately $5.3 million USD. The company considers the claim unfounded and intends to defend vigorously. No provision has been made for this liability.
- R&D Status: Proprietary candidates K1.1 (liver cancer) and SBFM-PL4 (SARS-CoV-2) remain in animal testing stages. Recent publications indicate promising antiviral activity for SBFM-PL4.
- Tax Legislation: The "One Big Beautiful Bill Act" (OBBBA) was enacted in July 2025. Management does not currently believe it will have a material impact on income tax expense.
Investor Verification Checklist
- Verify the status and potential financial impact of the $5.3 million legal claim filed by the former president of Nora Pharma.
- Confirm the commercial viability of the 17 drugs anticipated for launch in 2026 and the timeline for regulatory approval.
- Monitor the company's ability to reduce Cost of Goods Sold to the targeted 60% level to achieve breakeven.
- Review the dilution impact of outstanding warrants, specifically the 15.5 million Series B Warrants with an exercise price of $2.07.
- Assess the sustainability of the 33.6% gross margin given the company's reliance on government reimbursement programs in Canada.